The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
Drug treatments in Alzheimer’s disease
Open accessAbstract
Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer's disease (AD) and these act to control symptoms rather than alter the course of the disease. Studies of potential disease-modifying therapy have generally been undertaken in patients with clinically detectable disease, yet evidence suggests that the pathological changes associated with AD begin several years before this. It is possible that pharmacological therapy may be beneficial in this pre-clinical stage before the neurodegenerative process is established. Techniques providing earlier diagnosis, such as cerebrospinal fluid biomarkers and amyloid positron emission tomography neuroimaging, are key to testing this theory in clinical trials. Recent results from trials of agents such as aducanumab are encouraging but must also be interpreted with caution. Such medicines could potentially delay the onset of dementia and would therefore markedly reduce its prevalence. However, we currently remain a good distance away from clinically available disease-modifying therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current treatments for AD, including cholinesterase inhibitors and memantine, offer limited symptom relief, especially in the early to moderate stages, but do not halt disease progression or address the underlying neurodegeneration.”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Four drugs (donepezil, memantine, galantamine, rivastigmine) are approved on the market and belong to two families: anticholinesterase inhibitors and anti-glutaminergics.”
From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [155]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Research works printed but not linked: 1
- Mosconi, 2010, Pre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging, J Alzheimers Dis, 20, 843, 10.3233/JAD-2010-091504 · DOI
Cited by
Sorted by citations
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629
Interaction between Aβ and Tau in the Pathogenesis of Alzheimer’s Disease
Zhang, H., Wei, W., Zhao, M., Ma, L., Jiang, X., Pei, H., Cao, Y., & Li, H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.57078 · Cited by 689
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
“Drug development has targeted amyloid plaque formation, but other novel targets need to be explored [155].”
BackgroundBlood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy
Zhou, Y., Zhu, F., Liu, Y., Zheng, M., Wang, Y., Zhang, D., Anraku, Y., Zou, Y., Li, J., Wu, H., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc7031 · Cited by 304
Cannabinoids: Therapeutic Use in Clinical Practice
Pagano, C., Navarra, G., Coppola, L., Avilia, G., Bifulco, M., & Laezza, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063344 · Cited by 261
Kou, J., Shi, J.-Z., He, Y., Hao, J.-J., Zhang, H.-Y., Dong-mei, L., Song, J.-K., Yan, Y., Xie, X., Du, G., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00702-8 · Cited by 232
Efferth, T., & Oesch, F. (2021) · Medicinal Research Reviews · doi:10.1002/med.21842 · Cited by 225
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease
Li, Q., He, S., Chen, Y., Feng, F., Qu, W., & Sun, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.031 · Cited by 217
Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease
Bulck, M. V., Sierra‐Magro, A., Alarcón-Gil, J., Pérez‐Castillo, A., & Morales-Garcia, J. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030719 · Cited by 186
Payne, A., Nahashon, S. N., Taka, E., Adinew, G. M., & Soliman, K. F. A. (2022) · Biomolecules · doi:10.3390/biom12030371 · Cited by 174
Su, W., Gu, X., Dou, M., Duan, Q., Jiang, Z., Yin, K., Cai, W.-C., Cao, B., Wang, Y., & Chen, Y. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-331142 · Cited by 169
He, Z., Li, X., Wang, Z., Cao, Y., Han, S., Li, N., Cai, J., Cheng, S., & Liu, Q. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102848 · Cited by 150
Stem cell therapy for Alzheimer's disease
Liu, X., Yang, L.-P., & Zhao, L. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i8.787 · Cited by 162
Iron Homeostasis Disorder and Alzheimer’s Disease
Peng, Y., Chang, X., & Lang, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212442 · Cited by 146
Huang, Y., Zhao, M., Chen, X., Zhang, R., Le, A., Hong, M., Zhang, Y., Jia, L., Zang, W., Jiang, C., et al. (2023) · Aging and disease · doi:10.14336/ad.2022.0916 · Cited by 138
“Therefore, acetylcholinesterase and butyrylcholinesterase inhibitors remain FDAapproved drugs for the treatment of AD [153], including rivastigmine and galantamine [154].”
BackgroundCognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy
Huber, C. M., Yee, C., May, T., Dhanala, A., & Mitchell, C. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170490 · Cited by 136
Moreira, N. C. D. S., Lima, J. E. B. D. F., Marchiori, M. F., Carvalho, I., & Sakamoto‐Hojo, E. T. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210061 · Cited by 137
Alugoju, P., Swamy, V., Anthikapalli, N. V. A., & Tencomnao, T. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2084600 · Cited by 123
Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Beshir, S. A., Aadithsoorya, A. M., Parveen, A., Goh, S. S. L., Hussain, N., & Menon, V. B. (2022) · International Journal of Alzheimer s Disease · doi:10.1155/2022/9343514 · Cited by 129
Wu, J., Yu, Y., Wan, Y., Xia, J., Xu, J., Zhang, L., Liu, D., Chen, L., Tang, F., Ao, H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113207 · Cited by 119
Single-cell RNA sequencing reveals B cell–related molecular biomarkers for Alzheimer’s disease
Xiong, L.-L., Xue, L.-L., Du, R.-L., Niu, R.-Z., Chen, L., Chen, J., Hu, Q., Tan, Y.-X., Shang, H.-F., Liu, J., et al. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00714-8 · Cited by 114
Hammond, T. C., Xing, X., Wang, C., Ma, D., Nho, K. T., Crane, P. K., Elahi, F. M., Ziegler, D. A., Liang, G., Cheng, Q. S., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-1079-x · Cited by 115
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108
Effects of neural stem cell transplantation in Alzheimer’s disease models
Hayashi, Y., Lin, H.-T., Lee, C.-C., & Tsai, K. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-0622-x · Cited by 106
Du, C., Feng, W., Dai, X., Wang, J., Geng, D., Li, X., Chen, Y., & Zhang, J. (2022) · Small · doi:10.1002/smll.202203031 · Cited by 104
García-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104
Advances in Alzheimer’s disease’s pharmacological treatment
Filho, C. E. C., Loss, L. B., Pereira, C. M., Rossoni, J. V., Barcelos, R. M., Chiarelli-Neto, O., da Silva, B. S., Ambrósio, R. P., Castro, F. C. D. A. Q., Teixeira, S. F., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1101452 · Cited by 107
Modulation of Amyloid States by Molecular ChaperonesPreprint
Wentink, A. S., Nussbaum-Krammer, C. I., & Bukau, B. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033969 · Cited by 93
Marešová, P., Hruška, J., Klímová, B., Baraković, S., & Krejcar, O. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s264688 · Cited by 91
Zhou, Y., Ge, Y., Liu, Q., Li, Y., Xu, C., Guan, J., Diwu, Y., & Zhang, Q. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.10.028 · Cited by 91
Glucose metabolism, neural cell senescence and Alzheimer's disease
Wang, Q., Duan, L., Li, X., Wang, Y., Guo, W., Guan, F., & Ma, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084351 · Cited by 90
Current Pharmacotherapy and Multi-Target Approaches for Alzheimer’s Disease
Cheong, S. L., Tiew, J. K., Fong, Y. H., Leong, H. W., Chan, Y. M., Chan, Z. L., & Kong, E. W. J. (2022) · Pharmaceuticals · doi:10.3390/ph15121560 · Cited by 94
Contributions by the Brain Renin-Angiotensin System to Memory, Cognition, and Alzheimer’s Disease
Wright, J. W., & Harding, J. W. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181035 · Cited by 88
Cell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery
Cetin, S., Knez, D., Gobec, S., Kos, J., & Pišlar, A. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112924 · Cited by 92
Mesenchymal Stem Cell Therapy for Alzheimer's Disease
Hernández, A. E., & García, E. (2021) · Stem Cells International · doi:10.1155/2021/7834421 · Cited by 74
Gao, Y., Li, J., Wu, Q.-L., Wang, S., Yang, S., Li, X., Chen, N., Li, L., & Zhang, L. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108002 · Cited by 81
Witika, B. A., Poka, M., Demana, P. H., Matafwali, S. K., Melamane, S., Khamanga, S. M., & Makoni, P. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040836 · Cited by 85
Kong, Y. R., Tay, K. C., Su, Y. X., Wong, C. K., Tan, W., & Khaw, K. Y. (2021) · Molecules · doi:10.3390/molecules26030728 · Cited by 79
Yu, Y., Li, W., Mao, L., Peng, W., Long, D., Li, D., Zhou, R., & Dang, X. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1929257 · Cited by 80
Duan, L., Li, X., Ji, R., Hao, Z., Kong, M., Wen, X., Guan, F., & Ma, S. (2023) · Polymers · doi:10.3390/polym15092196 · Cited by 83
Remembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Li, Y., Sang, S., Ren, W., Pei, Y., Bian, Y., Chen, Y., & Sun, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113874 · Cited by 77
Baluchnejadmojarad, T., Mohamadi-Zarch, S.-M., & Roghani, M. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00481-6 · Cited by 75
Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer’s disease
Taliyan, R., Kakoty, V., Sarathlal, K. C., Kharavtekar, S. S., Karennanavar, C. R., Choudhary, Y. K., Singhvi, G., Riadi, Y., Dubey, S. K., & Kesharwani, P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.044 · Cited by 79
Haddad, H. W., Malone, G. W., Comardelle, N. J., Degueure, A. E., Kaye, A. M., & Kaye, A. D. (2022) · Health Psychology Research · doi:10.52965/001c.31925 · Cited by 77
Pharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty
Ibrahim, N. H., Yahaya, M. F., Mohamed, W. M. Y., Teoh, S. L., Hui, C. K., & Kumar, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00261 · Cited by 77
Lv, J., Lü, C., Jiang, N., Wang, H., Huang, H. M., Chen, Y., Li, Y., & Liu, X. (2020) · Phytotherapy Research · doi:10.1002/ptr.6804 · Cited by 72
Hepnarová, V., Korábečný, J., Matoušková, L., Jošt, P., Múčková, Ľ., Hrabinová, M., Vykoukalova, N., Kerhartova, M., Kucera, T., Doležal, R., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.083 · Cited by 72
Dietary Polyphenols as Therapeutic Intervention for Alzheimer’s Disease: A Mechanistic Insight
Bukhari, S. N. A. (2022) · Antioxidants · doi:10.3390/antiox11030554 · Cited by 71
Phytotherapy: A promising approach for the treatment of Alzheimer's disease
John, O. O., Amarachi, I. S., Chinazom, A. P., Adaeze, E., Kale, M. B., Umare, M. D., & Upaganlawar, A. B. (2022) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2021.100030 · Cited by 69
Pantiya, P., Thonusin, C., Chattipakorn, N., & Chattipakorn, S. C. (2020) · Mitochondrion · doi:10.1016/j.mito.2020.08.003 · Cited by 66
Riccardi, C., Napolitano, F., Montesarchio, D., Sampaolo, S., & Melone, M. A. B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111897 · Cited by 70
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Lian, W., Zhou, W., Zhang, B.-Y., Jia, H., Xu, L., Liu, A., & Du, G. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00506-2 · Cited by 60
Hambali, A., Kumar, J., Hashim, N. F. M., Maniam, S., Mehat, M. Z., Cheema, M. S., Mustapha, M., Adenan, M. I., Stanslas, J., & Hamid, H. A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.712317 · Cited by 65
Sectoral segmentation of retinal amyloid imaging in subjects with cognitive decline
Dumitrascu, O. M., Lyden, P. D., Torbati, T., Sheyn, J., Sherzai, A. Z., Sherzai, D., Sherman, D. S., Rosenberry, R., Cheng, S. C., Johnson, K., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12109 · Cited by 61
Pires, P. C., Paiva‐Santos, A. C., & Veiga, F. (2023) · Pharmaceuticals · doi:10.3390/ph16101424 · Cited by 61
Liao, J., He, W., Li, L., Wang, J., Gong, L., Zhang, Q., & Lin, Z. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100016 · Cited by 63
Dhamodharan, G., & Mohan, C. G. (2022) · Molecular Diversity · doi:10.1007/s11030-021-10282-8 · Cited by 56
Bott, N. T., Hall, A., Madero, E. N., Glenn, J. M., Fuseya, N., Gills, J. L., & Gray, M. (2019) · Nutrients · doi:10.3390/nu11092258 · Cited by 58
Li, S., Guo, Y., Men, J., Fu, H., & Xu, T. (2021) · BMC Geriatrics · doi:10.1186/s12877-021-02253-3 · Cited by 55
Siddappaji, K. K., & Gopal, S. (2021) · AIMS neuroscience · doi:10.3934/neuroscience.2021020 · Cited by 58
Islam, F., Islam, M. R., Meem, A. F. K., Nafady, M. H., Islam, M. R., Akter, A., Mitra, S., Alhumaydhi, F. A., Emran, T. B., Khusro, A., et al. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.136020 · Cited by 55
RetractedRostamikia, M., Sarbaz, Y., & Makouei, S. (2024) · Cognitive Neurodynamics · doi:10.1007/s11571-024-10152-7 · Cited by 62
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
Bascuñana, P., Möhle, L., Brackhan, M., & Pahnke, J. (2020) · Drugs in R&D · doi:10.1007/s40268-020-00316-1 · Cited by 57
van Groen, T., Schemmert, S., Brener, O., Gremer, L., Ziehm, T., Tusche, M., Nagel‐Steger, L., Kadish, I., Schartmann, E., Elfgen, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16565-1 · Cited by 53
Body mass index trajectories and the risk for Alzheimer’s disease among older adults
Kang, S. Y., Kim, Y., Jang, W., Son, K. Y., Park, H. S., & Kim, Y. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-82593-7 · Cited by 56
The Molecular Effects of Environmental Enrichment on Alzheimer’s Disease
Liew, A. K. Y., Teo, C. H., & Soga, T. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03016-w · Cited by 61
Cao, F., Liu, Z., & Sun, G. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110814 · Cited by 53
Quantum Dots as A Theranostic Approach in Alzheimer’s Disease: A Systematic Review
Villalva, M. D., Agarwal, V., Ulanova, M., Sachdev, P. S., & Braidy, N. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0104 · Cited by 53
Fan, M., Liu, S., Sun, H.-M., Ma, M.-D., Gao, Y.-J., Qi, C.-C., Xia, Q.-R., & Ge, J.-F. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113375 · Cited by 50
Ribeiro, V. T., de Souza, L. C., & Silva, A. C. S. E. (2019) · Protein and Peptide Letters · doi:10.2174/0929866527666191230103739 · Cited by 50
Lithium prevents scopolamine-induced memory impairment in zebrafish
Zanandrea, R., de Abreu, M. S., Piato, Â., Barcellos, L. J. G., & Giacomini, A. C. V. V. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.11.010 · Cited by 53
Petralia, M. C., Battaglia, G., Bruno, V., Pennisi, M., Mangano, K., Lombardo, S. D., Fagone, P., Cavalli, E., Saraceno, A., Nicoletti, F., et al. (2020) · Molecules · doi:10.3390/molecules25020291 · Cited by 50
Nakamichi, N., Nakao, S., Nishiyama, M., Takeda, Y., Ishimoto, T., Masuo, Y., Matsumoto, S., Suzuki, M., & Kato, Y. (2020) · Current Molecular Pharmacology · doi:10.2174/1874467213666200212102710 · Cited by 50
Recent developments of small molecule γ-secretase modulators for Alzheimer's disease
Mekala, S., Nelson, G. L., & Li, Y. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00196a · Cited by 51
Wojtunik‐Kulesza, K. A., Rudkowska, M., Kasprzak‐Drozd, K., Oniszczuk, A., & Borowicz, K. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147366 · Cited by 51
Li, X., Wang, S.-W., Li, X., Yu, F.-Y., & Cong, H. (2020) · Inflammation Research · doi:10.1007/s00011-020-01364-8 · Cited by 48
RetractedScoping review: the empowerment of Alzheimer’s Disease caregivers with mHealth applications
Kim, E., Baskys, A., Law, A. V., Roosan, M. R., Yan, L., & Roosan, D. (2021) · npj Digital Medicine · doi:10.1038/s41746-021-00506-4 · Cited by 47
Yasukawa, T., Tsutsui, A., Tomomori‐Sato, C., Sato, S., Saraf, A., Washburn, M. P., Florens, L. A., Terada, T., Shimizu, K., Conaway, R., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.059 · Cited by 43
Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases
Moosavi, S. G., Rahiman, N., Jaafari, M. R., & Arabi, L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113641 · Cited by 54
Sodium Butyrate Protects N2a Cells against Aβ Toxicity In Vitro
Sun, J., Yuan, B., Wu, Y., Gong, Y., Guo, W., Fu, S., Luan, Y., & Wang, W. (2020) · Mediators of Inflammation · doi:10.1155/2020/7605160 · Cited by 47
Fan, L., Qiu, X., Zhu, Z., Lv, J., Lu, J., Mao, F., Zhu, J., Wang, J., Guan, X., Chen, J., et al. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0220-1 · Cited by 46
Albadrani, H. M., Chauhan, P., Ashique, S., Babu, M. A., Iqbal, D., Almutary, A. G., Abomughaid, M. M., Kamal, M., Paiva‐Santos, A. C., Alsaweed, M., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116376 · Cited by 46
Wu, L., Du, Q., & Wu, C. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147622 · Cited by 44
Momtaz, S., Memariani, Z., El‐Senduny, F. F., Sanadgol, N., Golab, F., Katebi, M., Abdolghaffari, A. H., Farzaei, M. H., & Abdollahi, M. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00361 · Cited by 46
Longitudinal Speech Biomarkers for Automated Alzheimer's Detection
Laguarta, J., Hueto, F., Rajasekaran, P., Sarma, S. E., & Subirana, B. (2021) · Frontiers in Computer Science · doi:10.3389/fcomp.2021.624694 · Cited by 50
Effect of glycyrrhizic acid on scopolamine-induced cognitive impairment in mice
Ban, J. Y., Park, H. K., & Kim, S. K. (2020) · International Neurourology Journal · doi:10.5213/inj.2040154.077 · Cited by 40
Aghamohammad, S., Hafezi, A., & Rohani, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114816 · Cited by 40
Neuromodulation Treatments for Geriatric Mood and Cognitive Disorders
McDonald, W. M. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.08.014 · Cited by 40
Han, K., Sun, C., Jia, N., Li, R., Zhang, Z., & Zhong, Y. (2020) · Folia Neuropathologica · doi:10.5114/fn.2020.94002 · Cited by 40
Zhang, C., Hu, L., Liu, D., Huang, J., & Lin, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00760 · Cited by 41
Shi, J., Li, Y., Zhang, Y., Chen, J., Gao, J., Zhang, T., Shang, X., & Zhang, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794458 · Cited by 38
Qiao, Y., Gu, J., Yu, M., Chi, Y., & Ma, Y. (2024) · CNS Drugs · doi:10.1007/s40263-024-01067-2 · Cited by 38
A closer look at the mycobiome in Alzheimer’s disease: Fungal species, pathogenesis and transmission
Phuna, Z. X., & Madhavan, P. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15599 · Cited by 41
Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target
Wang, Y., Yan, T., Lu, H., Yin, W., Lin, B., Fan, W., Zhang, X., & Fernández-Fúnez, P. (2017) · Neurodegenerative Diseases · doi:10.1159/000478741 · Cited by 39
New Possibilities in the Therapeutic Approach to Alzheimer’s Disease
Doroszkiewicz, J., & Mroczko, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168902 · Cited by 46
Alzheimer’s Disease: A Systems View Provides a Unifying Explanation of Its Development
Grobler, C., van Tongeren, M., Gettemans, J., Kell, D. B., & Pretorius, E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220720 · Cited by 45
Chemical modulation of Kv7 potassium channels
Borgini, M., Mondal, P., Liu, R., & Wipf, P. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00328j · Cited by 37
Metadata
- Authors
- Briggs, R., Kennelly, S. P., & O’Neill, D.
- Affiliations
- Tallaght University Hospital (IE)
- Venue
- Clinical Medicine
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 16
- Issue
- 3
- Pages
- 247-253
- ISSN
- 1470-2118 (ISSN-L)
- PMC
- PMC5922703
- OpenAlex
- W2415242066
- Cited by
- 571
- References
- 76
- Citations by year
- 2026: 37 · 2025: 67 · 2024: 97 · 2023: 79 · 2022: 106 · 2021: 95 · 2020: 55 · 2019: 18 · 2018: 5 · 2017: 9 · 2016: 2
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Medicine (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, pharmacotherapy, disease-modifying therapy, symptomatic treatment, preclinical Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid PET, aducanumab, early diagnosis, dementia prevention
- MeSH terms
- Alzheimer Disease, Amyloid, Cholinesterase Inhibitors, Humans, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
